1D4細(xì)胞

是否是腫瘤細(xì)胞： 0

物種來(lái)源： 小鼠

ATCC Number： HB-8068?

數(shù)量： 大量

生長(zhǎng)狀態(tài)： 懸浮生長(zhǎng)

細(xì)胞形態(tài)： **樣

**類型： IgG1

運(yùn)輸方式： 凍存運(yùn)輸

Designations: 1D4

1D4細(xì)胞Depositors: The United States of America

Isotype: IgG1

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Mus musculus (B cell); Mus musculus (myeloma)

Morphology: lymphoblast

Source: Cell Type: hybridoma: B lymphocyte;

Cellular Products: immunoglobulin; monoclonal antibody; against nucleocapsid (p40) of herpes simplex virus type 1 (HSV-1)

Permits/Forms: 1D4細(xì)胞In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Tumorigenic: Yes

Comments: The original deposit of this cell line was contaminated with microorganisms. The line was treated with antibiotics and is now cured of the contamination. Animals were immunized with purified HSV-1 nucleocapsids.

Spleen cells were fused with P3-NSI/1-Ag4-1 myeloma cells.

The antibody precipitates p40 and p45 of HSV-1 but not HSV-2.

The supernatant may have to be concentrated for use.

Propagation: ATCC complete growth medium: RPMI 1640 medium with 1 mM sodium pyruvate and antibiotics, 15%; fetal bovine serum, 15%

Subculturing: 1D4細(xì)胞Medium Renewal: Every 2 to 3 days

Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.

Preservation: culture medium, 70%; fetal bovine serum, 20%; DMSO, 10%

References: 1004: Zweig M, et al. Production of monoclonal antibodies against nucleocapsid proteins of Herpes simplex Virus types 1 and 2. J. Virol. 32: 676-678, 1979. PubMed: 91687

3510: Zweig M, et al. 1D4細(xì)胞Test methods employing monoclonal antibodies against Herpes simplex virus types 1 and 2 nucleocapsids proteins. US Patent 4,430,437 dated Feb 7 1984